Vanila Mathur Singh, MD
Anesthesiology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Singh’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A78654 · Current
Licensed to practise in California · since 2002 · expires 2027-12-31 · George Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$23,465
Medicare paid this office $23,465 for 172 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 68 | $11,274 | $102 |
| New patient visit (60+ min) | 26 | $4,489 | $173 |
| Long return visit (40+ min) | 13 | $1,669 | $128 |
| Injection of trigger points, 3 or more muscles | 33 | $1,429 | $35 |
| Injection of trigger points, 1-2 muscles | 14 | $495 | $29 |
Who their Medicare patients are
172 Original Medicare patients in 2024. Average age 73 · Under 65 12% · 85 and older 9% · Women 68% · Also on Medicaid 22% · Health risk score 1.56. Above the middle of the specialty; the typical anesthesiology clinician is at 1.54.
Conditions among them: High blood pressure 70% · Diabetes 32% · Depression 30% · Coronary heart disease 25% · Chronic kidney disease 24% · Cancer 19% · Atrial fibrillation 19% · Heart failure 18% · COPD 14% · Stroke 9% · Dementia 8%.
The office billed $155,435, Medicare allowed $30,813 and paid $23,465; for 283 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 172 | 283 | 73 | 1.56 | $155,435 | $23,465 |
| 2023 | 189 | 303 | 71 | 1.50 | $181,647 | $25,053 |
| 2022 | 174 | 258 | 70 | 1.69 | $152,813 | $19,428 |
| 2021 | 166 | 302 | 69 | 1.64 | $256,009 | $23,530 |
| 2020 | 132 | 241 | 67 | 1.50 | $118,457 | $15,811 |
| 2019 | 37 | 56 | 70 | 1.40 | $25,335 | $3,451 |
| 2017 | 123 | 190 | 67 | 1.47 | $65,179 | $12,009 |
| 2016 | 176 | 312 | 69 | 1.54 | $145,511 | $22,611 |
| 2015 | 143 | 262 | 69 | 1.74 | $162,952 | $22,175 |
| 2014 | 59 | 96 | 67 | 1.31 | $70,317 | $10,087 |
| 2013 | 237 | 444 | 68 | 1.39 | $203,198 | $29,545 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 71 | $8,489 | $83 |
| Long return visit (40+ min) | 49 | $6,640 | $125 |
| New patient visit (60+ min) | 27 | $3,935 | $146 |
| Injection of trigger points, 3 or more muscles | 24 | $1,080 | $35 |
2022: 5 services
| Return visit (30+ min) | 61 | $6,247 | $78 |
| Long return visit (40+ min) | 33 | $4,324 | $124 |
| New patient visit (60+ min) | 28 | $3,906 | $140 |
| Injection of trigger points, 3 or more muscles | 28 | $1,284 | $34 |
| Injection of trigger points, 1-2 muscles | 13 | $464 | $31 |
2021: 6 services
| New patient visit (60+ min) | 45 | $7,300 | $162 |
| Return visit (30+ min) | 48 | $5,527 | $86 |
| Long return visit (40+ min) | 24 | $3,324 | $128 |
| Ultrasonic guidance for needle placement | 28 | $1,036 | $28 |
| Injection of trigger points, 3 or more muscles | 20 | $886 | $34 |
| Ultrasonic guidance for needle placement | 21 | $543 | $26 |
2020: 6 services
| Return visit (30+ min) | 37 | $4,339 | $68 |
| New patient visit (45+ min) | 30 | $3,353 | $112 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $1,350 | $96 |
| Injection of trigger points, 3 or more muscles | 12 | $664 | $37 |
| Ultrasonic guidance for needle placement | 19 | $574 | $27 |
| Ultrasonic guidance for needle placement | 15 | $438 | $29 |
2017: 5 services
| Return visit (30+ min) | 54 | $3,901 | $56 |
| New patient visit (45+ min) | 12 | $1,150 | $96 |
| Ultrasonic guidance for needle placement | 17 | $522 | $29 |
| Injection of trigger points, 3 or more muscles | 13 | $471 | $31 |
| Ultrasonic guidance for needle placement | 14 | $408 | $29 |
2016: 8 services
| Return visit (30+ min) | 34 | $3,611 | $67 |
| New patient visit (45+ min) | 34 | $3,297 | $97 |
| Continuous infusion of anesthetic agent and/or steroid into thigh nerve (femoral nerve) through catheter | 21 | $1,269 | $60 |
| Ultrasonic guidance for needle placement | 35 | $1,200 | $30 |
| Ultrasonic guidance for needle placement | 32 | $960 | $30 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 15 | $784 | $49 |
| Injection of trigger points, 3 or more muscles | 14 | $631 | $39 |
| Injection of trigger points, 1-2 muscles | 12 | $399 | $33 |
2015: 4 services
| Return visit (30+ min) | 24 | $2,667 | $65 |
| New patient visit (45+ min) | 19 | $2,108 | $111 |
| Ultrasonic guidance for needle placement | 58 | $1,761 | $29 |
| Continuous infusion of anesthetic agent and/or steroid into thigh nerve (femoral nerve) through catheter | 24 | $1,453 | $61 |
2014: 1 service
| Ultrasonic guidance for needle placement | 19 | $599 | $30 |
2013: 11 services
| Return visit (30+ min) | 45 | $4,229 | $63 |
| Ultrasonic guidance for needle placement | 125 | $3,694 | $29 |
| Anesthesia for procedure on nerves, muscles, tendons, and tissue of forearm, wrist, and hand | 11 | $1,818 | $165 |
| Continuous infusion of anesthetic agent and/or steroid into thigh nerve (femoral nerve) through catheter | 27 | $1,623 | $60 |
| New patient visit (60+ min) | 11 | $1,612 | $147 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 39 | $1,544 | $39 |
| Long return visit (40+ min) | 13 | $1,540 | $96 |
| Continuous infusion of anesthetic agent and/or steroid into arm nerve bundle through catheter | 21 | $1,405 | $67 |
| New patient visit (30+ min) | 17 | $999 | $59 |
| Injection of anesthetic agent and/or steroid into arm nerve bundle (brachial plexus) | 16 | $880 | $55 |
| Continuous infusion of anesthetic agent and/or steroid into lower back and leg nerve (sciatic nerve) through catheter | 11 | $736 | $67 |
Drugs they prescribed that Part D paid
$12,272
Pharmacies billed $12,272 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
287 generic and 12 brand-name prescriptions · $12,272 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lidocaine | 26 | $6,398 | $246 |
| Duloxetine | 92 | $2,139 | $23 |
| Pregabalin | 41 | $1,080 | $26 |
| Gabapentin | 69 | $1,000 | $14 |
| Nortriptyline | 16 | $251 | $16 |
See all 6 drugs
| Lidocaine | 26 | $6,398 | $246 |
| Duloxetine | 92 | $2,139 | $23 |
| Pregabalin | 41 | $1,080 | $26 |
| Gabapentin | 69 | $1,000 | $14 |
| Nortriptyline | 16 | $251 | $16 |
| Tizanidine | 13 | $238 | $18 |
Year by year
| 2024 | 299 | 59 | None | 4% | $12,272 |
| 2023 | 297 | 66 | 4% (11) | None | $10,155 |
| 2022 | 187 | 40 | None | None | $7,236 |
| 2021 | 135 | 41 | None | 8% | $10,312 |
| 2020 | 88 | 24 | None | None | $1,932 |
| 2019 | 12 | None | None | None | $1,110 |
| 2017 | 142 | 36 | None | None | $7,771 |
| 2016 | 78 | 25 | None | None | $4,028 |
| 2015 | 62 | 12 | None | None | $6,124 |
| 2014 | 17 | 11 | 0% (0) | None | $1,807 |
| 2013 | 94 | 35 | 36% (34) | 22% | $7,132 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Pregabalin | 48 | $2,385 | $50 |
| Duloxetine | 89 | $2,367 | $27 |
| Gabapentin | 78 | $1,938 | $25 |
| Nortriptyline | 16 | $284 | $18 |
| Cyclobenzaprine | 11 | $141 | $13 |
2022: 4 drugs
| Lidocaine | 15 | $2,257 | $150 |
| Duloxetine | 62 | $1,848 | $30 |
| Pregabalin | 30 | $1,187 | $40 |
| Gabapentin | 39 | $1,002 | $26 |
2021: 3 drugs
| Pregabalin | 28 | $1,342 | $48 |
| Duloxetine | 43 | $1,242 | $29 |
| Gabapentin | 12 | $277 | $23 |
2020: 3 drugs
| Duloxetine | 34 | $722 | $21 |
| Gabapentin | 15 | $345 | $23 |
| Nortriptyline | 15 | $152 | $10 |
2017: 4 drugs
| Duloxetine | 48 | $1,570 | $33 |
| Tizanidine | 13 | $264 | $20 |
| Gabapentin | 24 | $157 | $7 |
| Meloxicam | 11 | $32 | $3 |
2016: 2 drugs
| Duloxetine | 28 | $995 | $36 |
| Gabapentin | 15 | $124 | $8 |
2015: 1 drug
| Duloxetine | 23 | $1,593 | $69 |
2013: 3 drugs
| Gabapentin | 19 | $1,255 | $66 |
| Hydrocodone-Acetaminophen | 12 | $165 | $14 |
| Meloxicam | 11 | $78 | $7 |
Money from drug and device companies
$338 in 2025
| 2025 | 3 | 3 | None | $338 |
| 2024 | 3 | 3 | None | $323 |
| 2023 | 1 | 1 | None | $193 |
| 2021 | 1 | 1 | None | $130 |
| 2020 | 1 | 1 | None | $15,000 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Brixton Biosciences | Neural Ice | $239 | 1 payment
|
| Boston Scientific | Wavewriter Alpha Prime 16 | $59 | 1 payment
|
| Saluda Medical Americas | Evoke | $40 | 1 payment
|
See all 3 published payments
| Boston Scientific | Meals · 2025-09-18 | Wavewriter Alpha Prime 16 | $59 |
| Brixton Biosciences | Meals · 2025-08-22 | Neural Ice | $239 |
| Saluda Medical Americas | Meals · 2025-02-25 | Evoke | $40 |
See earlier years (2024, 2023, 2021, 2020)
2024: $323
| Medtronic | Intellis Adaptivestim | $152 | 1 payment
|
| Curonix | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A | $98 | 1 payment
|
| SPR Therapeutics | Sprint Pns System | $73 | 1 payment
|
2023: $193
| Saluda Medical Americas | Evoke Scs | $193 | 1 payment
|
2021: $130
| Boston Scientific | General - Pain Management | $130 | 1 payment
|
2020: $15,000
| SPR Therapeutics | Sprint Pns System | $15,000 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1588705180
- Licence
- CA A78654California A78654: Current · expires 2027-12-31
- Trained
- George Washington University School of Medicine, 1997
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A786540
- Taxonomy
- Federal specialty code 207L00000X (207L00000X); Federal specialty code 207LP2900X (207LP2900X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-08
- NPI last updated
- 2024-04-10
- NPI record certified
- 2024-04-10
This is when the NPI record was last certified, not a medical board exam.